Gisela Schwab
September 7, 2021 07:33 AM EDTUpdated 10:44 AM
People

Ex­elix­is mourns the deaths of two long­time ex­ec­u­tives

Nicole DeFeudis

Editor

Ex­elix­is is griev­ing the loss of two long­time ex­ec­u­tives this week, one of whom suc­cumbed to a lengthy bat­tle with can­cer and the oth­er of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk’s amy­cretin prompts 22% weight loss in ear­ly obe­si­ty tri­al

Obe­si­ty biotech Aard­vark files for IPO to ad­vance oral, hunger-sup­press­ing drug

Mod­er­na in­for­ma­tion chief to re­tire next month; Pharm­ing looks to Flag­ship for first new CEO since 2008

The cru­cial obe­si­ty da­ta to watch for this year

ALX On­col­o­gy to make case for ac­cel­er­at­ed ap­proval with new evor­pacept da­ta in gas­tric can­cer

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times